Finally, this study suggests that small-molecule targeting of the BCL10-MALT1 interaction holds promise as a therapeutic strategy for an even broader range of B and T cell malignancies that, like ABC-DLBCL, also depend on constitutive MALT1 signaling, as well as for selected autoimmune disorders. This evidence concerns the gene BCL10 and diffuse large B-cell lymphoma.